Susumu S Kobayashi
Overview
Explore the profile of Susumu S Kobayashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Uehara Y, Izumi H, Kobayashi I, Matsumoto S, Hosomi Y, Okuno T, et al.
Lung Cancer
. 2025 Mar;
202:108479.
PMID: 40088581
Background: EGFR exon 19 insertions (EGFRex19ins) are rare EGFR mutations. Their clinical-genomic characteristics and outcomes with EGFR-tyrosine kinase inhibitors (TKIs) remain uncertain. Methods: We evaluated the clinical-genomic characteristics and outcomes...
2.
Yamamoto G, Tanaka K, Kamata R, Saito H, Yamamori-Morita T, Nakao T, et al.
Cancer Lett
. 2024 Dec;
611:217414.
PMID: 39725152
KRAS inhibitors sotorasib and adagrasib have been approved for the treatment of KRAS-mutant non-small cell lung cancer (NSCLC). However, the efficacy of single-agent treatments is limited, presumably due to multiple...
3.
Izumi M, Fujii M, Kobayashi I, Ho V, Kashima Y, Udagawa H, et al.
Cell Death Dis
. 2024 Aug;
15(8):580.
PMID: 39122703
In EGFR-mutated lung cancer, the duration of response to tyrosine kinase inhibitors (TKIs) is limited by the development of acquired drug resistance. Despite the crucial role played by apoptosis-related genes...
4.
Izumi M, Costa D, Kobayashi S
Lung Cancer
. 2024 Jul;
194:107885.
PMID: 39002493
The advent of targeted therapies revolutionized treatments of advanced oncogene-driven non-small cell lung cancer (NSCLC). Nonetheless, despite initial dramatic responses, development of drug resistance is inevitable. Although mechanisms underlying acquired...
5.
Mori S, Izumi H, Araki M, Liu J, Tanaka Y, Kagawa Y, et al.
Commun Biol
. 2024 Apr;
7(1):412.
PMID: 38575808
The CLIP1-LTK fusion was recently discovered as a novel oncogenic driver in non-small cell lung cancer (NSCLC). Lorlatinib, a third-generation ALK inhibitor, exhibited a dramatic clinical response in a NSCLC...
6.
Viray H, Piper-Vallillo A, Widick P, Academia E, Shea M, Rangachari D, et al.
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539415
Osimertinib is a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) that is used for first-line therapy in mutated non-small cell lung cancer (NSCLC) based on the results...
7.
Qin Z, Yue M, Tang S, Wu F, Sun H, Li Y, et al.
J Exp Med
. 2024 Jan;
221(3).
PMID: 38284990
Human lung adenosquamous cell carcinoma (LUAS), containing both adenomatous and squamous pathologies, exhibits strong cancer plasticity. We find that ALK rearrangement is detectable in 5.1-7.5% of human LUAS, and transgenic...
8.
Kobayashi I, Shaffer W, Viray H, Rangachari D, VanderLaan P, Kobayashi S, et al.
JTO Clin Res Rep
. 2024 Jan;
5(1):100614.
PMID: 38229766
Introduction: Mechanisms of resistance to EGFR exon 20 insertion mutation active inhibitors have not been extensively studied in either robust preclinical models or patient-derived rebiopsy specimens. We sought to characterize...
9.
Yu Q, Kobayashi S, Haeno H
Front Oncol
. 2023 Oct;
13:1137966.
PMID: 37841421
Introduction: In Asians, more than half of non-small cell lung cancers (NSCLC) are induced by epidermal growth factor receptor (EGFR) mutations. Although patients carrying EGFR driver mutations display a good...
10.
Tabata S, Umemura S, Narita M, Udagawa H, Ishikawa T, Tsuboi M, et al.
Mol Cancer Res
. 2023 Sep;
22(1):82-93.
PMID: 37773022
Implications: SCLC tumors preferentially utilize either the de novo or salvage pathway in purine nucleotide biosynthesis, and HPRT1 has therapeutic implications in SCLC.